Versigent Ltd's stock price surged 8.27% during intraday trading on Wednesday, following a series of positive analyst actions.

The rally was driven by multiple investment banks raising their price targets for the company. UBS increased its target to $49 from $43, while Wells Fargo raised its target to $42 from $35. Wells Fargo also reiterated its Buy rating on the stock.

According to analyst polls, Versigent maintains an average Buy rating with a mean price target of $43.67, indicating continued optimism about the company's prospects among financial institutions.